Skip Header
Important information: The value of investments can go down as well as up so you may get back less than you invest. Investors should note that the views expressed may no longer be current and may have already been acted upon. This is a third-party news feed and may not reflect Fidelity’s views.

UBS upgrades Entain to 'buy', shares spark

(Sharecast News) - UBS upgraded Entain on Tuesday to 'buy' from 'neutral' and lifted the price target to 920p from 820p. It said the Ladbrokes owner has been steadily progressing on its key operational frontiers over the past year, yet the shares have underperformed, declining 8% in a rising sector.

"In short, the company is yet to be rewarded for its underlying improvements through 2024," UBS said.

"We see 2025-26 as a catalytic 'come back' period as Entain continues to deliver in its online business, proves out sustainable profitability in BetMGM and inflects to free cash flow profitability."

The bank said Entain is the cheapest amid peers and offers the highest level of earnings growth relative to its multiple.

"The group trades on a circa 9% FY26 free cash flow yield, a 20% discount to peers and offers a +20% compound annual growth rate out to 2029E on FCF/share," it said.

"We see catalysts in H1 trading via guidance upgrades for Entain online and BetMGM."

At 1500 BST, Entain shares were up 5.9% at 763.20p.

Share this article

Related Sharecast Articles

GSK gets preliminary nod for two respiratory drugs in Europe
(Sharecast News) - GSK said on Friday afternoon that two of its respiratory medicines had received positive opinions from the European Medicines Agency's Committee for Medicinal Products for Human Use, bringing the company closer to potential approvals across severe asthma, chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease.
Shore Capital hails improved US biotech funding environment for hVIVO
(Sharecast News) - Shares in AIM-listed hVIVO were continuing their recent surge on the back of encouraging signs from the US biotech market, which broker Shore Capital said has created a "much more favourable environment" for the company.
Weir to buy remaining 50% stake in Chile JV ESEL for £56m
(Sharecast News) - Weir said on Friday that it has agreed to buy the remaining 50% share of its Chile-based joint venture ESEL for a sterling equivalent purchase price of £56m.
Jefferies downgrades Whitbread, upgrades IHG
(Sharecast News) - Jefferies downgraded Whitbread to 'hold' from 'buy' on Friday as it applied the reverse upgrade to InterContinental Hotels.

Important information: This information is not a personal recommendation for any particular investment. If you are unsure about the suitability of an investment you should speak to one of Fidelity’s advisers or an authorised financial adviser of your choice. When you are thinking about investing in shares, it’s generally a good idea to consider holding them alongside other investments in a diversified portfolio of assets. Past performance is not a reliable indicator of future returns.

Award-winning online share dealing

Search, compare and select from thousands of shares.

Expert insights into investing your money

Our team of experts explore the world of share dealing.